Table 3.

Prognostic factors for overall survival.

Variables	(ref. vs. test)	Univariable analysis			Multivariable analysis
		HR	95% CI	P-value	HR	95% CI	P-value
Age	(<60 vs. ≥ 60 yrs)	0.65	0.47-0.90	0.010	0.58	0.35-0.95	0.030
Pathology	(Non-SRC vs. SRC)	1.39	0.86-2.26	0.179
BMI (kg/m2)	(≥18.5 vs. <18.5)	1.99	1.35-2.92	<0.001	1.79	0.98-3.28	0.058
Molecular category	MSS/EBV negative	Ref.			Ref.
	MSI-H	0.18	0.08-0.40	<0.001	0.08	0.03-0.28	<0.001
	EBV positive	0.45	0.22-0.92	0.029	0.76	0.29-1.99	0.577
PD-L1 (22C3 CPS)	(<1% vs. ≥ 1%)	0.51	0.35-0.76	0.001	1.16	0.68-1.99	0.584
ICB	(Nivolumabvs. Pembrolizumab)	0.55	0.40-0.78	0.001	0.98	0.56-1.71	0.942
ICB sequence	(After 1st line vs. 2nd or more line)	0.79	0.57-1.09	0.153
Metastatic sites	(<2 vs. ≥2)	1.49	1.03-2.17	0.035	1.53	0.87-2.66	0.138
Previous curative surgery	(No vs. yes)	0.78	0.55-1.11	0.164
Radiation therapy	(No vs. yes)	0.62	0.40-0.96	0.033	0.47	0.24-0.92	0.028
Interval between radiation therapy and ICB	(<6 vs. ≥6 months)	0.81	0.63-1.04	0.092
Baseline albumin	(≥3.5 vs. <3.5 g/dL)	2.16	1.50-3.11	<0.001	1.34	0.95-1.88	0.094
Number of risk factors(sarcopenia & NLR≥3)	0	Ref.			Ref.
	1	1.23	0.83-1.82	0.300	2.02	1.09-3.74	0.026
	2	2.39	1.56-3.66	<0.001	6.06	3.04-12.08	<0.001

*The foreparts of parentheses are set as the reference group.

HR, hazard ratio; CI, confidence interval; SRC, signet ring cell carcinoma; BMI, body mass index; MSS, microsatellite stable; EBV, Epstein-Barr virus; MSI-H, microsatellite instability-high; PD-L1, programmed death-ligand 1; CPS, combined positive score; ICB, immune-checkpoint blockade; NLR, neutrophil-lymphocyte ratio.